Limited simulation CTL epitope of tumor antigen Ran HLA-A*0201 and uses thereof

A tumor antigen, limited technology, applied in the direction of anti-tumor drugs, antibody medical ingredients, medical preparations containing active ingredients, etc. Effects of killing effect, strong affinity, and binding stability

Inactive Publication Date: 2009-08-19
ARMY MEDICAL UNIV
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the main methods of clinical treatment of tumors include surgical resection, radiotherapy and chemotherap...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Limited simulation CTL epitope of tumor antigen Ran HLA-A*0201 and uses thereof
  • Limited simulation CTL epitope of tumor antigen Ran HLA-A*0201 and uses thereof
  • Limited simulation CTL epitope of tumor antigen Ran HLA-A*0201 and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0020] Hereinafter, preferred embodiments of the present invention will be described in detail with reference to the accompanying drawings.

[0021] Ran HLA-A predicted and preliminarily identified in the previous research of the present invention * 0201 Restricted natural CTL epitope: IMFDVTSRV (referred to as Ran1), TLGVEVHPL (referred to as Ran2) and YVATLGVEV (referred to as Ran3) as the basis, according to HLA-A * 0201 Restricted epitope motif (the main anchoring residues are the 2nd and 9th amino acid residues, wherein the 2nd amino acid residue is L or M, and the 9th amino acid residue is L, I or V) and other positions of different amino acid residues on the epitope and HLA-A * 0201 The impact of molecular affinity, the main anchoring residues of the above three natural CTL epitopes or the amino acid residues at their adjacent positions are modified so that the CTL epitopes do not contain amino acid residues that are not conducive to binding or that are conducive to bi...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses tumor antigen Ran HLA-A0201 restricted simulated CTL epitope which is composed of Tyr-Met-Phe-Asp-Val-Thr-Ser-Arg-Val amino acid sequence. Compared with a natural CTL epitope, the simulated CTL epitope has stronger affinity and combination stability with HLA-A0201 molecules; meanwhile, the specific CTL induced by the simulated CTL epitope has IFN-gamma with higher level, and the specific CTL has stronger antigen-specific killing effect on positive MCF-7 cells of the HLA-A0201 and the Ran as well as T2 cells loading with the natural CTL epitope; and the tumor antigen Ran is widely expressed in different tumor tissues. The simulated CTL epitope can be used for preparing therapeutic polypeptide vaccine of Ran positive tumors, and the simulated CTL epitope has good development and application prospect in the tumor-specific immunotherapy field.

Description

technical field [0001] The invention relates to a tumor antigen mimic epitope, in particular to the tumor antigen Ran HLA-A * 0201 restrictively mimics a cytotoxic T lymphocyte (CTL) epitope, and also relates to the application of the simulated CTL epitope. Background technique [0002] Malignant tumor is one of the major diseases that threaten human life and health. Its morbidity and mortality are increasing year by year. It ranks first in the cause of death of urban residents in my country. It is imminent to take effective prevention and treatment for it. At present, the main methods for clinical treatment of tumors include surgical resection, radiotherapy and chemotherapy, but the therapeutic effects of these methods on some tumors, especially advanced malignant tumors, are not satisfactory. Tumor-specific immunotherapy and tumor therapeutic peptide vaccines, which have been developed rapidly in recent years, are based on the CTL epitopes of tumor antigens, activate the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K7/06A61K39/00A61P35/00
Inventor 吴玉章倪兵李凡
Owner ARMY MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap